Cargando…
Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer
Pancreatic cancer is a highly aggressive form of cancer with a five-year survival rate of only ten percent. Pancreatic ductal adenocarcinoma (PDAC) accounts for ninety percent of those cases. PDAC is associated with a dense stroma that confers resistance to current treatment modalities. Increasing r...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425600/ https://www.ncbi.nlm.nih.gov/pubmed/37588093 http://dx.doi.org/10.3389/fonc.2023.1217095 |
_version_ | 1785089875004882944 |
---|---|
author | Henderson, Emily A. Lukomski, Slawomir Boone, Brian A. |
author_facet | Henderson, Emily A. Lukomski, Slawomir Boone, Brian A. |
author_sort | Henderson, Emily A. |
collection | PubMed |
description | Pancreatic cancer is a highly aggressive form of cancer with a five-year survival rate of only ten percent. Pancreatic ductal adenocarcinoma (PDAC) accounts for ninety percent of those cases. PDAC is associated with a dense stroma that confers resistance to current treatment modalities. Increasing resistance to cancer treatments poses a challenge and a need for alternative therapies. Bacterial mediated cancer therapies were proposed in the late 1800s by Dr. William Coley when he injected osteosarcoma patients with live streptococci or a fabrication of heat-killed Streptococcus pyogenes and Serratia marcescens known as Coley’s toxin. Since then, several bacteria have gained recognition for possible roles in potentiating treatment response, enhancing anti-tumor immunity, and alleviating adverse effects to standard treatment options. This review highlights key bacterial mechanisms and structures that promote anti-tumor immunity, challenges and risks associated with bacterial mediated cancer therapies, and applications and opportunities for use in PDAC management. |
format | Online Article Text |
id | pubmed-10425600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104256002023-08-16 Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer Henderson, Emily A. Lukomski, Slawomir Boone, Brian A. Front Oncol Oncology Pancreatic cancer is a highly aggressive form of cancer with a five-year survival rate of only ten percent. Pancreatic ductal adenocarcinoma (PDAC) accounts for ninety percent of those cases. PDAC is associated with a dense stroma that confers resistance to current treatment modalities. Increasing resistance to cancer treatments poses a challenge and a need for alternative therapies. Bacterial mediated cancer therapies were proposed in the late 1800s by Dr. William Coley when he injected osteosarcoma patients with live streptococci or a fabrication of heat-killed Streptococcus pyogenes and Serratia marcescens known as Coley’s toxin. Since then, several bacteria have gained recognition for possible roles in potentiating treatment response, enhancing anti-tumor immunity, and alleviating adverse effects to standard treatment options. This review highlights key bacterial mechanisms and structures that promote anti-tumor immunity, challenges and risks associated with bacterial mediated cancer therapies, and applications and opportunities for use in PDAC management. Frontiers Media S.A. 2023-07-19 /pmc/articles/PMC10425600/ /pubmed/37588093 http://dx.doi.org/10.3389/fonc.2023.1217095 Text en Copyright © 2023 Henderson, Lukomski and Boone https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Henderson, Emily A. Lukomski, Slawomir Boone, Brian A. Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer |
title | Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer |
title_full | Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer |
title_fullStr | Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer |
title_full_unstemmed | Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer |
title_short | Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer |
title_sort | emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425600/ https://www.ncbi.nlm.nih.gov/pubmed/37588093 http://dx.doi.org/10.3389/fonc.2023.1217095 |
work_keys_str_mv | AT hendersonemilya emergingapplicationsofcancerbacteriotherapytowardstreatmentofpancreaticcancer AT lukomskislawomir emergingapplicationsofcancerbacteriotherapytowardstreatmentofpancreaticcancer AT boonebriana emergingapplicationsofcancerbacteriotherapytowardstreatmentofpancreaticcancer |